MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Aurigene Discovery Technologies Limited
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Stanford University
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Institute of Hematology and Blood Transfusion, Czech Republic
M.D. Anderson Cancer Center
Orca Biosystems, Inc.
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
BeOne Medicines
Fred Hutchinson Cancer Center
University of Manitoba
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Mayo Clinic
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Chordia Therapeutics, Inc.
University of Alabama at Birmingham
GluBio Therapeutics Inc.
National Cancer Institute (NCI)
Beijing InnoCare Pharma Tech Co., Ltd.
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Miami
M.D. Anderson Cancer Center
PedAL BCU, LLC
Stanford University
TScan Therapeutics, Inc.
Bristol-Myers Squibb
Seagen Inc.
University of Arizona
Massachusetts General Hospital
Changchun GeneScience Pharmaceutical Co., Ltd.
Ohio State University Comprehensive Cancer Center
Hackensack Meridian Health
Dana-Farber Cancer Institute
Taiho Oncology, Inc.
University of Rochester
Mayo Clinic
M.D. Anderson Cancer Center
Incyte Corporation